Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IAPP | P10997 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CTH | P32929 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10072095 | 0.81 | IAPP (0.53) | IAPPRAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL1510820 | 0.77 | CA12 (0.49) | RAB9ANPC1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL1510817 | 0.77 | CA12 (0.49) | RAB9ANPC1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL1914087 | 0.76 | KDM4E (0.50) | RAB9ANPC1KDM4EALDH1A1TSHR | |
| SCHEMBL1914082 | 0.76 | KDM4E (0.50) | RAB9ANPC1KDM4EALDH1A1TSHR | |
| SCHEMBL17157997 | 0.72 | MEN1 (0.43) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL17157996 | 0.72 | MEN1 (0.43) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL16642332 | 0.71 | ALDH1A1 (0.38) | RAB9ANPC1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL19900075 | 0.71 | ALDH1A1 (0.38) | RAB9ANPC1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL30288729 | 0.71 | ALDH1A1 (0.38) | RAB9ANPC1KDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348312-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170348312-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348312-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | IAPP 4140/4885RAB9A 1415/4885NPC1 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.